FCM
ACAD icon

Fieldview Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Fieldview Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$844K Buy
33,368
+14,236
+74% +$313K 0.24% 113
2026
Q1 		$426K Buy
+19,132
New +$457K 0.12% 292

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fieldview Capital Management's ACAD Position: Q2 2026 in Review

Fieldview Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 74% in Q2 2026, buying an estimated $313K and bringing the position to 33,368 shares worth $844K. The position accounts for 0.24% of the portfolio, ranked #113.

Fieldview Capital Management first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Fieldview Capital Management held 33,368 shares of Acadia Pharmaceuticals worth $844K as of Q2 2026.
  • Fieldview Capital Management bought 14,236 Acadia Pharmaceuticals shares in Q2 2026, an estimated $313K.
  • Acadia Pharmaceuticals made up 0.24% of Fieldview Capital Management's portfolio in Q2 2026, its #113 holding.
  • Fieldview Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.